Joomla gallery extension by joomlashine.com
Main Promo Images
Latest news on Friedreich's Ataxia research
Updated results from clinical trials and research initiatives
Friedreich's Ataxia fundraising activities and staying in touch
Participate and stay informed about our fundraising events. Take part in our Facebook community with FA patients, relatives, researchers and friends from all around the world!
Memory Enhanced By Sports-cheat Drug
ScienceDaily (Sep. 9, 2008) — A drug used to increase blood production in both medical treatments and athletic doping scandals seems also to improve memory in those using it. New research shows that the memory enhancing effects of erythropoietin (EPO) are not related to its effects on blood production but due to direct influences on neurons in the brain.
The findings may prove useful in the treatment of diseases affecting brain function, such as schizophrenia, multiple sclerosis, and Alzheimer’s.
Patients given EPO to treat chronic kidney failure had been observed to have improved cognition after starting the drug. “These effects of EPO were thought to result from the blood-boosting effects of the drug”, explains Hannelore Ehrenreich at the Max Planck Institute, “but the finding of receptors for EPO on nerve cells in the brain suggests that some other mechanism might be involved.”
To investigate the mechanisms of EPO-enhanced cognition, the researchers injected mice with EPO every other day for three weeks (11 doses) to test the effects of long-term exposure. After the treatment period, mice given EPO had better memory in some situations than did mice that had been given a placebo instead. The improvement in memory lasted up to three weeks from the last EPO dose and outlasted increased blood-cell production, but had disappeared by four weeks. Mice given three doses saw no benefit with respect to memory improvement.
“Young mice systematically treated with EPO for three weeks have improved memory, similar to the dramatic improvements observed in endurance and muscular performance athletes who use EPO to boost performance”, says Ehrenreich. The specific memory improvements were associated with the hippocampus, a structure in the brain involved in learning and memory, among other functions.
The researchers did a series of experiments on hippocampal tissue taken from the mice and found that EPO directly affected the neurons in this structure. “EPO had pronounced effects on short-term and long-term plasticity in the hippocampus as well as on synaptic transmission”, the researchers report. “Treatment with EPO seems to increase the number of inhibitory circuits, which actually increases the efficiency of transmission of excitatory nerve impulses in specific neurons, resulting in greater short-term and long-term plasticity in memory pathways in the hippocampus.”
These findings begin to shed light on the mechanisms of improvements in cognition seen in patients with schizophrenia and multiple sclerosis as a result of treatment with this drug. As well as working to refine these findings, further studies might also investigate the effects of EPO on other brain regions that might be associated with improvements in motor functions in multiple sclerosis, and investigate the potential of using EPO or targeting the networks involved in EPO-generated neuronal plasticity in the treatment of neurodegenerative diseases.
Bartosz Adamcio, Derya Sargin, Alicja Stradomska, Lucian Medrihan, Christoph Gertler, Fabian Theis, Mingyue Zhang, Michael Müller, Imam Hassouna, Kathrin Hannke, Swetlana Sperling, Konstantin Radyushkin, Ahmed El-Kordi, Lizzy Schulze, Anja Ronnenberg, Fred Wolf, Nils Brose, Jeong-Seop Rhee, Weiqi Zhang and Hannelore Ehrenreich. Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biology, (in press)
If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.
The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.
Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!
Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:
1) Gene Therapy for Friedreich's Ataxia research project:
The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.
2) Frataxin delivery research project:
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.
The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.